{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:52:41Z","timestamp":1768647161776,"version":"3.49.0"},"reference-count":26,"publisher":"University of Tokushima Faculty of Medicine","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Invest."],"published-print":{"date-parts":[[2020]]},"DOI":"10.2152\/jmi.67.280","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T22:07:16Z","timestamp":1604527636000},"page":"280-284","source":"Crossref","is-referenced-by-count":13,"title":["Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus"],"prefix":"10.2152","volume":"67","author":[{"given":"Satoshi","family":"Shinozaki","sequence":"first","affiliation":[{"name":"Shinozaki Medical Clinic, Tochigi, Japan"},{"name":"Department of Medicine, Division of Gastroenterology, Jichi Medical University, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Tahara","sequence":"additional","affiliation":[{"name":"Saiseikai Utsunomiya Hospital, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Kawarai","family":"Lefor","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"925","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T\u2005:\u2005Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\u2006\/\u2006nonalcoholic steatohepatitis. J Gastroenterol 50\u2005:\u2005364-377, 2015","DOI":"10.1007\/s00535-015-1050-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T\u2005:\u2005Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan\u2005:\u2005a multicenter large retrospective study. J Gastroenterol 47\u2005:\u2005586-595, 2012","DOI":"10.1007\/s00535-012-0533-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R\u2005:\u2005Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 43\u2005:\u200583-95, 2016","DOI":"10.1111\/apt.13405"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Angulo P, Keach JC, Batts KP, Lindor KD\u2005:\u2005Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30\u2005:\u20051356-1362, 1999","DOI":"10.1002\/hep.510300604"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Azuma K, Kadowaki T, Cetinel C, Kadota A, El-Saed A, Kadowaki S, Edmundowicz D, Nishio Y, Sutton-Tyrrell K, Okamura T, Evans RW, Takamiya T, Ueshima H, Curb JD, Abbott RD, Kuller LH, Kelley DE, Sekikawa A\u2005:\u2005Higher liver fat content among Japanese in Japan compared with non-Hispanic whites in the United States. Metabolism 58\u2005:\u20051200-1207, 2009","DOI":"10.1016\/j.metabol.2009.03.021"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fujita Y, Inagaki N\u2005:\u2005Update on the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in Asians and non-Asians. J Diabetes Investig 10\u2005:\u20051408-1410, 2019","DOI":"10.1111\/jdi.13150"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tahrani AA, Barnett AH, Bailey CJ\u2005:\u2005SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1\u2005:\u2005140-151, 2013","DOI":"10.1016\/S2213-8587(13)70050-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y\u2005:\u2005Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8\u2005:\u200545, 2016","DOI":"10.1186\/s13098-016-0169-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sattar N, Fitchett D, Hantel S, George JT, Zinman B\u2005:\u2005 Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat\u2005:\u2005results from randomised trials including the EMPA-REG OUTCOME (R) trial. Diabetologia 61\u2005:\u20052155-2163, 2018","DOI":"10.1007\/s00125-018-4702-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T\u2005:\u2005Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin\u2005:\u2005an association with glucose-lowering effects. Endocr J 64\u2005:\u2005363-367, 2017","DOI":"10.1507\/endocrj.EJ16-0295"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A\u2005:\u2005Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease\u2005:\u2005A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care 41\u2005:\u20051801-1808, 2018","DOI":"10.2337\/dc18-0165"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, Yamaguchi S, Kanno K, Ogawa Y\u2005:\u2005Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One 11\u2005:\u2005e0151511, 2016","DOI":"10.1371\/journal.pone.0151511"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S\u2005:\u2005Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44\u2005:\u2005865-873, 2006","DOI":"10.1002\/hep.21327"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Kanemasa K, Yasui K, Minami M, Imai S, Itoh Y\u2005:\u2005Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 45\u2005:\u2005E53-61, 2015","DOI":"10.1111\/hepr.12456"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K\u2005:\u2005Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology\u2005:\u2005A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer 6\u2005:\u2005204-215, 2017","DOI":"10.1159\/000452846"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H\u2005:\u2005A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 3\u2005:\u20051065, 2013","DOI":"10.1038\/srep01065"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Sasaki R, Bekki S, Kugiyama Y, Miyazoe Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Yatsuhashi H\u2005:\u2005Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 60\u2005:\u20051563-1570, 2014","DOI":"10.1002\/hep.27305"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Narimatsu H\u2005:\u2005Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 50\u2005:\u2005776-784, 2015","DOI":"10.1007\/s00535-014-1007-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP\u2005:\u2005The NAFLD fibrosis score\u2005:\u2005a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45\u2005:\u2005846-854, 2007","DOI":"10.1002\/hep.21496"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, M SS, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M\u2005:\u2005Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\u2006\/\u2006HCV coinfection. Hepatology 43\u2005:\u20051317-1325, 2006","DOI":"10.1002\/hep.21178"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, Hori Y, Yano Y, Adachi Y\u2005:\u2005Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24\u2005:\u2005362-365, 2001","DOI":"10.2337\/diacare.24.2.362"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kahl S, Gancheva S, Strassburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K, Kupriyanova Y, Markgraf D, van Gemert T, Knebel B, Wolkersdorfer MF, Kuss O, Hwang JH, Bornstein SR, Kasperk C, Stefan N, Pfeiffer A, Birkenfeld AL, Roden M\u2005:\u2005Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes\u2005:\u2005A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care 43\u2005:\u2005298-305, 2020","DOI":"10.2337\/dc19-0641"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK\u2005:\u2005Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci 65\u2005:\u2005623-631, 2020","DOI":"10.1007\/s10620-019-5477-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Inoue M, Hayashi A, Taguchi T, Arai R, Sasaki S, Takano K, Inoue Y, Shichiri M\u2005:\u2005Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig 10\u2005:\u20051004-1011, 2019","DOI":"10.1111\/jdi.12980"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, Kawai H, Ohashi N, Mori A\u2005:\u2005Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease\u2005:\u2005A prospective randomized controlled pilot study. Diabetes Obes Metab 20\u2005:\u2005438-442, 2018","DOI":"10.1111\/dom.13061"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, Osonoi T\u2005:\u2005Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease\u2005:\u2005A prospective, single-arm trial (LEAD trial). Hepatol Res 49\u2005:\u200564-71, 2019","DOI":"10.1111\/hepr.13236"}],"container-title":["The Journal of Medical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/67\/3.4\/67_280\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:50:28Z","timestamp":1623113428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/67\/3.4\/67_280\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":26,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2152\/jmi.67.280","relation":{},"ISSN":["1343-1420","1349-6867"],"issn-type":[{"value":"1343-1420","type":"print"},{"value":"1349-6867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}